Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

This Increases Acute GVHD After Allo-HSCT

Biol Blood Marrow Transplant; ePub 2018 Jan 4; Hosoba, et al

Peri-transplant red blood cell (RBC) transfusions appear to increase the risk of developing severe acute graft-vs-host disease (aGVHD) and experiencing worse overall survival following allogeneic hematopoietic stem cell transplant (allo-HSCT), according to a retrospective study involving 322 individuals. Participants with hematological malignancies received RBC transfusion before either allogeneic bone marrow or granulocyte colony-stimulating factor-mobilized blood stem cell grafts. Among the results:

  • 1 in every 5 patients developed maximal grade of III-IV aGVHD.
  • Onset occurred up to 150 days post-transplant (median onset 28 days).
  • Patients with HLA mismatch and those with a higher number of RBC units were each >twice as likely to experience grade III-IV aGVHD.
  • High-risk patients and those receiving more median RBC units were independently linked with inferior overall survival.


Hosoba S, Waller E, Shenva N, et al. Peri-transplant RBC transfusion is associated with increased risk of GvHD after allogeneic stem cell transplantation. [Published online ahead of print January 4, 2018]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2018.01.003.

This Week's Must Reads

FDA postmarketing requirements, Nabhan C et al. JAMA Oncol. 2018 May 10. doi:10.1001/jamaoncol.2018.0610.

Upswing in childhood lymphomas, Siegel DA et al. ASPHO 2018, Abstract 605.

Dapagliflozin suppresses hepcidin, Ghanim HA et al. AACE 2018, Abstract 228.

Methotrexate or nelarabine plus chemo in pediatric T-ALL or T-L, Dunsmore KP et al. ASCO 2018, Abstract 10500.

Blood type is diarrhea destiny, Kumar P et al. J Clin Invest. 2018 May 17; doi: 10.1172/JCI97659.

Must Reads in Myelodysplastic Syndrome

Romiplostim safety confirmed in thrombocytopenic patients with low-risk myelodysplastic syndromes, Kantarjian H et al. The Lancet Haematology March 2018, Pages e117-e126

Simplifying the URD Selection Process for HCT, Biol Blood Marrow Transplant.; ePub 2018 Feb 14; Shaw, Logan, et al

Genetic Risk Model for MDS Shown to Be Feasible, Am J Hematol; ePub 2018 Feb 24; Gangat, et al

This Predicts Risk of Early Relapse, Death in MM , Biol Blood Marrow Transplant; ePub 2018 Feb 23; Cowan, et al

Undertreatment of Newly-Diagnosed MM Evaluated, Clin Lymphoma Myeloma Leuk; ePub 2018 Feb 3; Fakhri, et al